NGM Biopharmaceuticals (Nasdaq:NGM) - Aandelenkoers, Nieuws & Analyse

NGM Overzicht aandelen

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer.

Over het bedrijf

NGM fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 57.57% per jaar groeien

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen zinvolle omzet ( $4M )

NGM Biopharmaceuticals, Inc. Concurrenten

Clearside Biomedical

NasdaqGM:CLSD

US$75.5m

Ikena Oncology

NasdaqGM:IKNA

US$83.0m

Scilex Holding

NasdaqCM:SCLX

US$128.0m

Journey Medical

NasdaqCM:DERM

US$127.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor NGM Biopharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$1.54
52 Week Hoogtepunt	US$4.69
52 Week Laag	US$0.60
Bèta	1.27
11 maand verandering	1.32%
3 maanden verandering	14.93%
1 Jaar Verandering	-59.79%
33 jaar verandering	-93.94%
5 jaar verandering	-90.41%
Verandering sinds IPO	-89.52%

Recent nieuws en updates

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06

Rendement voor aandeelhouders

	NGM	US Pharmaceuticals	US Markt
7D	-3.1%	-3.4%	-1.2%
1Y	-59.8%	17.1%	30.6%

Rendement versus industrie: NGM presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 17.1 % opleverde.

Rendement versus markt: NGM presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.6 % opleverde.

Prijsvolatiliteit

Is NGM's price volatile compared to industry and market?
NGM volatility
NGM Average Weekly Movement	10.3%
Pharmaceuticals Industry Average Movement	9.3%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van NGM is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van NGM is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	138	David Woodhouse	www.ngmbio.com

NGM Biopharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van NGM Biopharmaceuticals zich tot de beurswaarde?
NGM fundamentele statistieken
Marktkapitalisatie	US$128.53m
Inkomsten(TTM)	-US$142.37m
Inkomsten(TTM)	US$4.42m

29.1x

P/S-verhouding

-0.9x

Koers/Winstverhouding

Is NGM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NGM resultatenrekening (TTM)
Inkomsten	US$4.42m
Kosten van inkomsten	US$114.23m
Brutowinst	-US$109.81m
Overige uitgaven	US$32.56m
Inkomsten	-US$142.37m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.71
Brutomarge	-2,486.12%
Nettowinstmarge	-3,223.34%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde NGM op de lange termijn?

Bekijk historische prestaties en vergelijking

NGM Overzicht aandelen

Beloningen

Risicoanalyse

NGM Biopharmaceuticals, Inc. Concurrenten

NasdaqGM:CLSD

US$75.5m

NasdaqGM:IKNA

US$83.0m

NasdaqCM:SCLX

US$128.0m

NasdaqCM:DERM

US$127.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals Files Form 15

The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders.

The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million.

NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer

Recent updates

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals Files Form 15

The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders.

The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million.

NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer

NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

NGM Biopharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NGM Biopharmaceuticals, Inc. Presents Positive Phase 2b Results from the Alpha 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target decreased by 19% to US$4.83

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Ngm Biopharmaceuticals, Inc. Appoints Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

NGM Biopharmaceuticals, Inc. Announces Appointment of Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

Consensus revenue estimates fall by 26%

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Consensus revenue estimates decrease by 47%, EPS upgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Consensus EPS estimates fall by 23%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Founder exercised options and sold US$316k worth of stock

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharmaceuticals, Inc. Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Price target increased to US$6.20

NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ngm Biopharmaceuticals, Inc. Announces Presentation of Post-Hoc Analyses from Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration At the Retina Society Annual Scientific Meeting

Lead Independent Director recently bought US$462k worth of stock

Ngm Biopharmaceuticals, Inc. (Ngm Bio) Announces Topline Efficacy and Safety Results from Its Randomized, Double-Masked, Sham-Controlled Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration

Price target decreased to US$28.75

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Consensus revenue estimates fall by 11%

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.48 loss in 2Q 2021)

Price target decreased to US$32.50

NGM Biopharmaceuticals, Inc. Announces Executive Changes

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. Announces Initiation of Phase 1/1B Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

Consensus forecasts updated

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

NGM Biopharmaceuticals, Inc. to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

NGM Biopharmaceuticals, Inc., Annual General Meeting, May 18, 2022

NGM Biopharmaceuticals, Inc. Announces It Has Dosed the First Patient in A Phase 1/1B Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

CEO & Director exercised options to buy US$313k worth of stock.

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely